FDA Approves Nivolumab Plus Ipilimumab for Malignant Pleural MesotheliomaOctober 3rd 2020
The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of adults with unresectable, malignant, pleural mesothelioma (MPM), according to Bristol Myers Squibb, the manufacturer of the immunotherapy agents.
FDA Approves Pralsetinib for RET Fusion Positive Metastatic NSCLCSeptember 5th 2020
The Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC), according to Genentech, the co-manufacturer of the drug.
On Clinicals and Coronavirus: COVID-19 Pandemic Shakes Up Nursing EducationAugust 30th 2020
The coronavirus disease 2019 (COVID-19) pandemic has affected nursing school at both the graduate and undergraduate level. While online classes may be convenient, a lack of in-person and hands-on training is a clear downside for those learning the trade.